{
    "clinical_study": {
        "@rank": "31865", 
        "arm_group": [
            {
                "arm_group_label": "zeaxanthin", 
                "arm_group_type": "Experimental", 
                "description": "placebo zeaxanthin"
            }, 
            {
                "arm_group_label": "combinatory supplement", 
                "arm_group_type": "Active Comparator", 
                "description": "placebo combinatory supplement"
            }
        ], 
        "brief_summary": {
            "textblock": "This study was designed to test whether two zeaxanthin formulations (supplements containing\n      different nutritional compounds with zeaxanthin and omega fatty acids being the primary\n      ingredients of interest) influenced visual motor function.  Visual motor function refers to\n      the processing speed of the visual system and how individuals respond behavioral to visual\n      stimuli (e.g., reaction time)."
        }, 
        "brief_title": "The Effects of a Zeaxanthin Intervention on Visuomotor Function", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Behavior and Behavior Mechanisms", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: \u226518 and \u2264 40 years\n\n          -  BMI: \u2265 20 and \u2264 30 kg/m2\n\n          -  No anticipated changes in dieting habits (as relevant to the intake of xanthophylls\n             and fats/oils).\n\n          -  No anticipated surgical procedures.\n\n          -  Willingness and ability to give written informed consent and willingness and ability\n             to comply with the study requirements.\n\n          -  Corrected visual acuity (ETDRS): better than 20/60 in the eye selected for the study\n\n        Exclusion Criteria:\n\n          -  Smokers\n\n          -  Current or history of relevant ocular diseases (such as AMD) or other conditions\n             e.g., lipid disorders.\n\n          -  Inability to reliably perform macular pigment optical density measurements by\n             \"Heterochromatic Flicker Photometry\" or any of the other ophthalmic tests of the\n             study.\n\n          -  Any condition likely to interfere with normal gastro-intestinal absorption of\n             xanthophylls (e.g., digestive disorders: inflammatory bowel disease, ulcerative\n             colitis, Crohn's, irritable bowel, etc. or lipid disorders including conditions such\n             as hypercholesterolemia)\n\n          -  Current use of xanthophyll containing supplements or use of xanthophyll containing\n             supplements in the past 6 months (but excluding multivitamins containing lutein or\n             zeaxanthin at low potency).\n\n          -  Participation in any other study during last 1 month before study initiation.\n\n          -  Known hypersensitivity or allergy to xanthophylls.\n\n          -  Regular intake of medications or supplements, which the principal investigator deems\n             likely to confound the study outcomes. These include diabetes medication and statins\n             or any other drug/supplement to modulate cholesterol or fat digestion/absorption."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02017418", 
            "org_study_id": "2012-10531"
        }, 
        "intervention": [
            {
                "arm_group_label": "zeaxanthin", 
                "intervention_name": "zeaxanthin", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "zeaxanthin"
            }, 
            {
                "arm_group_label": "combinatory supplement", 
                "intervention_name": "combinatory supplement", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "zeaxanthin + lutein + DHA"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "zeaxanthin", 
            "visual function", 
            "reaction time", 
            "processing speed"
        ], 
        "lastchanged_date": "December 23, 2013", 
        "location": {
            "contact": {
                "email": "bhammond@uga.edu", 
                "last_name": "Billy R Hammond, Ph.D.", 
                "phone": "706-542-4812"
            }, 
            "contact_backup": {
                "email": "erbovier@uga.edu", 
                "last_name": "Emily R Bovier, Ph.D.", 
                "phone": "706-542-4812"
            }, 
            "facility": {
                "address": {
                    "city": "Athens", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30602"
                }, 
                "name": "Department of Psychology, UGA"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effects of a Zeaxanthin Intervention on Visuomotor Function", 
        "overall_contact": {
            "email": "bhammond@uga.edu", 
            "last_name": "Billy R Hammond, Ph.D.", 
            "phone": "706-542-4812"
        }, 
        "overall_contact_backup": {
            "email": "erbovier@uga.edu", 
            "last_name": "Emily R Bovier, M.S", 
            "phone": "706-542-4812"
        }, 
        "overall_official": {
            "affiliation": "University of Georgia", 
            "last_name": "Billy R Hammond, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Increases in the amount of macular pigment measured in optical density units", 
            "measure": "Macular pigment optical density", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02017418"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Georgia", 
            "investigator_full_name": "Billy R. Hammond", 
            "investigator_title": "Professor and Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "reaction time to a stimulus fixed in space", 
                "measure": "fixed reaction time", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "reaction time to a stimulus with a position that varies in space", 
                "measure": "variable reaction time", 
                "safety_issue": "No", 
                "time_frame": "12-months"
            }, 
            {
                "description": "button press when a light stimulus of varying speeds reaches a specific point in a linear light array", 
                "measure": "coincidence anticipation", 
                "safety_issue": "No", 
                "time_frame": "12-months"
            }
        ], 
        "source": "University of Georgia", 
        "sponsors": {
            "collaborator": {
                "agency": "ZeaVision, LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Georgia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}